A unblinded review with 4,000 patient years of data, showed that TRT in post-menopausal women, who were at risk of experiencing CV events, reduced the number of CV events by at least 70% over expectations. It also reduced the number of CV events by an undisclosed amount over placebo. In 2015, they discovered that TRT reduced breast cancer events by an undisclosed amount over expectations. A finding not evident during the earlier review or when the trial was completed (December 2012). The discoveries are only public in patent applications, listing the Study Director, Dr. Michael C. Snabes (Senior Medical Director with AbbVie Global Clinical Research and Development) as one of the inventors.